LYRA Oct 2024 5.000 put
| Previous Close | 4.7000 |
| Open | 4.7000 |
| Bid | 4.4000 |
| Ask | 5.0000 |
| Strike | 5.00 |
| Expire Date | 2024-10-18 |
| Day's Range | 4.7000 - 4.7000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 30 |
GlobeNewswireLyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
WATERTOWN, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the Company will present results from the Phase 3 ENLIGHTEN 1 study for LYR-210, the company’s lead product candidate for CRS, at the 70th Annual Meeting of the American Rhinologic Society (ARS), taking place
Simply Wall St.Lyra Therapeutics Insiders Still US$66k Away From Original Investment Value
Insiders who bought US$74.1k worth of Lyra Therapeutics, Inc. ( NASDAQ:LYRA ) stock in the last year have seen some of...
ZacksLyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of 14.71% and 40.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
